Fatty acid synthase is up-regulated during hepatitis C virus infection and regulates hepatitis C virus entry and production

Hepatology

Volumn 48, Issue 5, 2008, Pages 1396-1403

  Yang, Wei ^a,d   Hood, Brian L ^a   Chadwick, Sara L ^a   Liu, Shufeng ^a   Watkins, Simon C ^b   Luo, Guangxiang ^c   Conrads, Thomas P ^a   Wang, Tianyi ^a  

^a UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

^b UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF KENTUCKY   (United States)

^d TSINGHUA UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

CD81 ANTIGEN; CLAUDIN 1; FATTY ACID SYNTHASE; FATTY ACID SYNTHASE INHIBITOR; VIRUS RNA;

ACUTE HEPATITIS; ARTICLE; CATALYST; CHRONIC HEPATITIS; ENZYME ACTIVITY; ENZYME INHIBITION; FATTY ACID SYNTHESIS; FATTY LIVER; GENOTYPE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; MASS SPECTROMETRY; MONOLAYER CULTURE; NONHUMAN; PRIORITY JOURNAL; PROTEIN DETERMINATION; PROTEIN EXPRESSION; PROTEIN PROTEIN INTERACTION; PROTEOMICS; REPLICON; RNA INTERFERENCE; UPREGULATION; VIROGENESIS; VIRUS CELL INTERACTION; VIRUS REPLICATION; VIRUS RESISTANCE; VIRUS VIRULENCE; CELL LINE; ENZYMOLOGY; GENETICS; KIDNEY; LIVER TUMOR; METABOLISM; PHYSIOLOGY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR CELL LINE; VIRION;

CELL LINE; CELL LINE, TUMOR; FATTY ACID SYNTHETASE COMPLEX; HEPACIVIRUS; HEPATITIS C; HUMANS; KIDNEY; LIVER NEOPLASMS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, VIRAL; UP-REGULATION; VIRION; VIRUS REPLICATION;

EID: 56149118610     PISSN: 02709139     EISSN: None     Source Type: Journal    
DOI: 10.1002/hep.22508     Document Type: Article

References (33)

1. Lindenbach BD, Rice CM. Molecular biology of flaviviruses. Adv Virus Res 2003;59:23-61.
2. Lindenbach BD, Rice CM. Unravelling hepatitis C virus replication from genome to function. Nature 2005;436:933-938.
3. Penin F, Dubuisson J, Rey FA, Moradpour D, Pawlotsky JM. Structural biology of hepatitis C virus. HEPATOLOGY 2004;39:5-19.
4. Bjornsson E, Angulo P. Hepatitis C and steatosis. Arch Med Res 2007;38: 621-627.
5. Maxwell KL, Frappier L. Viral proteomics. Microbiol Mol Biol Rev 2007; 71:398-411.
6. Scholle F, Li K, Bodola F, Ikeda M, Luxon BA, Lemon SM. Virus-host cell interactions during hepatitis C virus RNA replication: Impact of polyprotein expression on the cellular transcriptome and cell cycle association with viral RNA synthesis. J Virol 2004;78:1513-1524.
7. Yang W, Qiu C, Biswas N, Jin J, Watkins SC, Montelaro RC, et al. Correlation of the tight junction-like distribution of claudin-1 to the cellular tropism of HCV. J Biol Chem 2008;283:8643-8653.
8. Jiang WG, Bryce RP, Horrobin DF, Mansel RE. Regulation of tight junction permeability and occludin expression by polyunsaturated fatty acids. Biochem Biophys Res Commun 1998;244:414-420.
9. Chang KS, Jiang J, Cai Z, Luo G. Human apolipoprotein e is required for infectivity and production of hepatitis C virus in cell culture. J Virol 2007;81:13783-13793.
10. Menendez JA, Lupu R. Fatty acid synthase and the lipogenic phenotype in cancer pathogenesis. Nat Rev Cancer 2007;7:763-777.
11. Kridel SJ, Lowther WT, Pemble CWt. Fatty acid synthase inhibitors: New directions for oncology. Expert Opin Investig Drugs 2007;16:1817-1829.
12. Huang H, Sun F, Owen DM, Li W, Chen Y, Gale M Jr, et al. Hepatitis C virus production by human hepatocytes dependent on assembly and secretion of very low-density lipoproteins. Proc Natl Acad Sci U S A 2007;104: 5848-5853.
13. Kapadia SB, Chisari FV. Hepatitis C virus RNA replication is regulated by host geranylgeranylation and fatty acids. Proc Natl Acad Sci U S A 2005; 102:2561-2566.
14. Kuhajda FP, Pizer ES, Li JN, Mani NS, Frehywot GL, Townsend CA. Synthesis and antitumor activity of an inhibitor of fatty acid synthase. Proc Natl Acad Sci U S A 2000;97:3450-3454.
15. Orita H, Coulter J, Lemmon C, Tully E, Vadlamudi A, Medghalchi SM, et al. Selective inhibition of fatty acid synthase for lung cancer treatment. Clin Cancer Res 2007;13:7139-7145.
16. Bess JW Jr, Gorelick RJ, Bosche WJ, Henderson LE, Arthur LO. Microvesicles are a source of contaminating cellular proteins found in purified HIV-1 preparations. Virology 1997;230:134-144.
17. Gluschankof P, Mondor I, Gelderblom HR, Sattentau QJ. Cell membrane vesicles are a major contaminant of gradient-enriched human immuno-deficiency virus type-1 preparations. Virology 1997;230:125-133.
18. Diedrich G. How does hepatitis C virus enter cells? FEBS J 2006;273: 3871-3885.
19. Wang Y, Kuhajda FP, Li JN, Pizer ES, Han WF, Sokoll LJ, et al. Fatty acid synthase (FAS) expression in human breast cancer cell culture supernatants and in breast cancer patients. Cancer Lett 2001;167:99-104.
20. Wang YY, Kuhajda FP, Li J, Finch TT, Cheng P, Koh C, et al. Fatty acid synthase as a tumor marker: Its extracellular expression in human breast cancer. J Exp Ther Oncol 2004;4:101-110.
21. Weinman SA, Belalcazar LM. Hepatitis C: A metabolic liver disease. Gastroenterology 2004;126:917-919.
22. Su AI, Pezacki JP, Wodicka L, Brideau AD, Supekova L, Thimme R, et al. Genomic analysis of the host response to hepatitis C virus infection. Proc Natl Acad Sci U S A 2002;99:15669-15674.
23. Shi ST, Polyak SJ, Tu H, Taylor DR, Gretch DR, Lai MM. Hepatitis C virus NS5A colocalizes with the core protein on lipid droplets and interacts with apolipoproteins. Virology 2002;292:198-210.
24. Miyanari Y, Atsuzawa K, Usuda N, Watashi K, Hishiki T, Zayas M, et al. The lipid droplet is an important organelle for hepatitis C virus production. Nat Cell Biol 2007;9:1089-1097.
25. Jackel-Cram C, Babiuk LA, Liu Q. Up-regulation of fatty acid synthase promoter by hepatitis C virus core protein: Genotype-3a core has a stronger effect than genotype-1b core. J Hepatol 2007;46:999-1008.
26. Oem JK, Jackel-Cram C, Li YP, Zhou Y, Zhong J, Shimano H, et al. Activation of sterol regulatory element-binding protein 1c and fatty acid synthase transcription by hepatitis C virus non-structural protein 2. J Gen Virol 2008;89:1225-1230.
27. Rubbia-Brandt L, Quadri R, Abid K, Giostra E, Male PJ, Mentha G, et al. Hepatocyte steatosis is a cytopathic effect of hepatitis C virus genotype 3. J Hepatol 2000;33:106-115.
28. Aizaki H, Lee KJ, Sung VM, Ishiko H, Lai MM. Characterization of the hepatitis C virus RNA replication complex associated with lipid rafts. Virology 2004;324:450-461.
29. Egger D, Wolk B, Gosert R, Bianchi L, Blum HE, Moradpour D, et al. Expression of hepatitis C virus proteins induces distinct membrane alterations including a candidate viral replication complex. J Virol 2002;76:5974-5984.
30. Evans MJ, von Hahn T, Tscherne DM, Syder AJ, Panis M, Wolk B, et al. Claudin-1 is a hepatitis C virus co-receptor required for a late step in entry. Nature 2007;446:801-805.
31. Van Itallie CM, Anderson JM. The molecular physiology of tight junction pores. Physiology (Bethesda) 2004;19:331-338.
32. Schneeberger EE, Lynch RD. The tight junction: A multifunctional complex. Am J Physiol Cell Physiol 2004;286:C1213-1228.
33. Kapadia SB, Barth H, Baumert T, McKeating JA, Chisari FV. Initiation of hepatitis C virus infection is dependent on cholesterol and cooperativity between CD81 and scavenger receptor B type I. J Virol 2007;81:374-383.